Upstart's stock is surging after upbeat results and guidance. This could be the third consecutive major gain for the AI lending company's shares after earnings.

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Alix Steel, Scarlet Fu, Carol Massar and Tim Stenovec. -------- More on Bloomberg Television and Markets Like this video?

The Bank of N.T. Butterfield & Son Limited (NYSE:NTB ) Q4 2024 Earnings Conference Call February 11, 2025 10:00 AM ET Company Participants Noah Fields - Vice President of Investor Relations Michael Collins - Chairman and Chief Executive Officer Craig Bridgewater - Group Chief Financial Officer Michael Schrum - President and Group Chief Risk Officer Conference Call Participants David Feaster - Raymond James Timur Braziler - Wells Fargo Securities Tim Switzer - KBW Operator Good morning.

Shares of NVIDIA Corp. (NASDAQ: NVDA) was mostly flat on Tuesday, losing -0.58% after a strong five-day stretch that has seen the stock rise 9.10%.

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Outbrain Inc. (NASDAQ: OB), which is operating under the new Teads brand, today announced the successful closing of its Rule 144A/Reg S private offering (the “Offering”) of $637.5 million in aggregate principal amount of 10.000% senior secured notes due 2030 (the “Notes”) at an issue price of 98.087% of the principal amount thereof in a transaction exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”).

Luxembourg, Luxembourg--(Newsfile Corp. - February 11, 2025) - Nexa Resources S.A. (NYSE: NEXA) ("Nexa Resources", "Nexa", or "Company") is pleased to provide today the drilling and assay results from the fourth quarter and full year of 2024.

Freshworks forecast annual revenue and profit above Wall Street estimates on Tuesday, betting on growing demand for its enterprise software for managing digital operations, sending its shares up 6% in extended trading.

USA Compression Partners, LP Common Units (NYSE:USAC ) Q4 2024 Earnings Conference Call February 12, 2025 11:00 AM ET Company Participants Chris Porter - VP, General Counsel and Secretary Clint Green - President and CEO Chris Paulsen - CFO Conference Call Participants James Rollyson - Raymond James Gabe Moreen - Mizuho Jeremy Tonet - JPMorgan Brian DiRubbio - Baird Operator Good morning. Welcome to USA Compression Partners Fourth Quarter 2024 Earnings Conference Call.

SoFi Technologies, Inc. (NASDAQ:SOFI ) BofA Securities 2025 Financial Services Conference February 11, 2025 1:50 PM ET Company Participants Anthony Noto - Chief Executive Officer Conference Call Participants Mihir Bhatia - BofA Securities Mihir Bhatia Welcome to the SoFi Session. I'm Mehir Bhatia.

Food-delivery app DoorDash Inc. on Tuesday forecast a key demand metric to come in above Wall Street's expectations for the first quarter, as it adds more grocery stores to its platform to complement its core restaurant business.

On this week's episode of “ETF Prime,” host Nate Geraci was joined by Cinthia Murphy, investment strategist at VettaFi. Together, Murphy and Geraci discussed a number of topics, including fee cuts from Vanguard, Trump getting into ETFs, and more.

JACKSONVILLE, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) Executive Vice President and Chief Executive Officer, Joe Hinrichs, and Executive Vice President and Chief Financial Officer, Sean Pelkey, will address the 42nd Annual Barclays Industrial Select Conference in Miami Beach on Wednesday, February 19, at 8:40 a.m. ET.

LOS GATOS, CA / ACCESS Newswire / February 11, 2025 / Atomera Incorporated (NASDAQ:ATOM), a semiconductor materials and technology licensing company, today provided a corporate update and announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Company Highlights Continued progress toward commercialization at ST Microelectronics Expanded offerings for gate-all-around products, the foundation technology of the most advanced AI devices Newly initiated development efforts with two large customers Management Commentary "Recent progress with large customers has reinforced the attractiveness of MST to solve some of the most difficult problems faced by semiconductor companies, which is …

PARSIPPANY, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for the fourth quarter and full year ended December 31, 2024 today.

Fourth quarter net income of $1.21 per diluted share and adjusted operating income of $1.25 per diluted share; full year net income of $2.39 per diluted share and adjusted operating income of $2.56 per diluted share

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).

LAS VEGAS , Feb. 11, 2025 /PRNewswire/ -- Red Rock Resorts, Inc. ("Red Rock Resorts," "we" or the "Company") (NASDAQ: RRR) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Results Consolidated Operations Net revenues were $495.7 million for the fourth quarter of 2024, an increase of 7.1%, or $33.0 million, from $462.7 million in the same period of 2023.

-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 50 patients have had cells collected across all regions as of the end of 2024- -Clinical trials ongoing for next-generation CAR T product candidates, CTX112™ and CTX131™, targeting CD19 and CD70 across multiple indications; updates for CTX112 in oncology and autoimmune diseases are expected in mid-2025 with CTX131 updates expected in 2025- …

DXP Enterprises is making strides in the key end markets, which makes the stock worth a watch amid certain headwinds.

QMCO's focus on driving growth through innovative products, operational efficiency, and a subscription-based selling bodes well.